Small molecules in the treatment of systemic lupus erythematosus

Clinical Immunology

Volumn 148, Issue 3, 2013, Pages 359-368

  Markopoulou, Anastasia ^a   Kyttaris, Vasileios C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

HDAC inhibitors; Jak; Kinase inhibitors; Syk; Systemic lupus erythematosus

Indexed keywords

5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; BORTEZOMIB; BRUTON TYROSINE KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CARFILZOMIB; DELANZOMIB; DIPYRIDAMOLE; FASUDIL; FOSTAMATINIB; HYDROXAMIC ACID; IBRUTINIB; IMATINIB; JANUS KINASE; LAQUINIMOD; MAMMALIAN TARGET OF RAPAMYCIN; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; ONX 0914; PAQUINIMOD; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEASOME; PROTEIN KINASE SYK; RAPAMYCIN; RHO KINASE; RUXOLITINIB; TACROLIMUS; TOFACITINIB; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTHRALGIA; ASTHMA; BACKACHE; BLEEDING; BRAIN VASOSPASM; BRONCHOSPASM; CALCIUM CELL LEVEL; CHROMATIN; CHRONIC MYELOID LEUKEMIA; DRUG BINDING; DRUG EFFICACY; ENZYME INHIBITION; EPIGENETICS; HUMAN; INNATE IMMUNITY; MYALGIA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VASODILATATION;

HDAC INHIBITORS; JAK; KINASE INHIBITORS; SYK; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 4; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JANUS KINASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEASOME INHIBITORS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RHO-ASSOCIATED KINASES;

EID: 84881112674     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.09.009     Document Type: Review

References (103)

1. Tsokos G.C. Systemic lupus erythematosus. N. Engl. J. Med. 2011, 365:2110-2121.
2. Druker B.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344:1031-1037.
3. Pamuk O.N., Tsokos G.C. Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases. Arthritis Res. Ther. 2010, 12:222.
4. Ghosh D., Tsokos G.C. Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases. Autoimmunity 2010, 43:48-55.
5. Kyttaris V.C., Tsokos G.C. Syk kinase as a treatment target for therapy in autoimmune diseases. Clin. Immunol. 2007, 124:235-237.
6. Liossis S.N., Ding X.Z., Dennis G.J., Tsokos G.C. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J. Clin. Invest. 1998, 101:1448-1457.
7. Enyedy E.J., Nambiar M.P., Liossis S.N., Dennis G., Kammer G.M., Tsokos G.C. Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum. 2001, 44:1114-1121.
8. Krishnan S., Warke V.G., Nambiar M.P., Tsokos G.C., Farber D.L. The FcR gamma subunit and Syk kinase replace the CD3 zeta-chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells. J. Immunol. 2003, 170:4189-4195.
9. Nambiar M.P., Fisher C.U., Kumar A., Tsokos C.G., Warke V.G., Tsokos G.C. Forced expression of the Fc receptor gamma-chain renders human T cells hyperresponsive to TCR/CD3 stimulation. J. Immunol. 2003, 170:2871-2876.
10. Krishnan S., et al. Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J. Immunol. 2004, 172:7821-7831.
11. Krishnan S., et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J. Immunol. 2008, 181:8145-8152.
12. Weinblatt M.E., Kavanaugh A., Genovese M.C., Musser T.K., Grossbard E.B., Magilavy D.B. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 2010, 363:1303-1312.
13. Genovese M.C., et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011, 63:337-345.
14. Bahjat F.R., et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 2008, 58:1433-1444.
15. Deng G.M., Liu L., Bahjat F.R., Pine P.R., Tsokos G.C. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 2010, 62:2086-2092.
16. O'Shea J.J., Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012, 36:542-550.
17. Macchi P., et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995, 377:65-68.
18. Russell S.M., et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995, 270:797-800.
19. O'Shea J.J., et al. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol. Immunol. 2004, 41:727-737.
20. Kralovics R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352:1779-1790.
21. Boisson-Dupuis S., et al. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr. Opin. Immunol. Aug 2012, 24(4):364-378.
22. Fleischmann R., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 2012, 367:495-507.
23. van Vollenhoven R.F., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 2012, 367:508-519.
24. Verstovsek S., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 2012, 366:799-807.
25. Harrison C., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 2012, 366:787-798.
26. Kalliolias G.D., Ivashkiv L.B. Overview of the biology of type I interferons. Arthritis Res. Ther. 2010, 12(Suppl. 1):S1.
27. Kalliolias G.D., Kirou K.A. Type I interferons as biomarkers in autoimmune diseases. Biomark. Med. 2012, 6:137-140.
28. Apostolidis S.A., Lieberman L.A., Kis-Toth K., Crispin J.C., Tsokos G.C. The dysregulation of cytokine networks in systemic lupus erythematosus. J. Interferon Cytokine Res. 2011, 31:769-779.
29. Davis L.S., Hutcheson J., Mohan C. The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J. Interferon Cytokine Res. 2011, 31:781-789.
30. Wang S., et al. Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice. Lupus 2010, 19:1171-1180.
31. Lu L.D., et al. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. J. Immunol. 2011, 187:3840-3853.
32. Mohamed A.J., et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol. Rev. 2009, 228:58-73.
33. Ng Y.S., Wardemann H., Chelnis J., Cunningham-Rundles C., Meffre E. Bruton's tyrosine kinase is essential for human B cell tolerance. J. Exp. Med. 2004, 200:927-934.
34. Honigberg L.A., et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13075-13080.
35. Juang Y.T., et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J. Clin. Invest. 2005, 115:996-1005.
36. Ichinose K., Juang Y.T., Crispin J.C., Kis-Toth K., Tsokos G.C. Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. Arthritis Rheum. 2011, 63:523-529.
37. Ichinose K., et al. Cutting edge: calcium/calmodulin-dependent protein kinase type IV is essential for mesangial cell proliferation and lupus nephritis. J. Immunol. 2011, 187:5500-5504.
38. Apostolidis S.A., Crispin J.C., Tsokos G.C. IL-17-producing T cells in lupus nephritis. Lupus 2011, 20:120-124.
39. Li Y., et al. Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J. Immunol. 2007, 178:1938-1947.
40. Biswas P.S., et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J. Clin. Invest. 2010, 120:3280-3295.
41. Lech M., et al. IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production. J. Am. Soc. Nephrol. 2011, 22:1443-1452.
42. Stirzaker R., Biswas P., Gupta S., Song L., Bhagat G., Pernis A. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. Lupus 2012, 21:656-661.
43. Suzuki Y., Shibuya M., Satoh S., Sugimoto Y., Takakura K. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg. Neurol. 2007, 68:126-131. (discussion 131-122).
44. Vicari R.M., et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J. Am. Coll. Cardiol. 2005, 46:1803-1811.
45. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
46. Warner L.M., Adams L.M., Sehgal S.N. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum. 1994, 37:289-297.
47. Ramos-Barron A., et al. Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment. Lupus 2007, 16:775-781.
48. Lui S.L., et al. Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice. Lupus 2008, 17:305-313.
49. Lui S.L., et al. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. Nephrol. Dial. Transplant. 2008, 23:2768-2776.
50. Fernandez D., Perl A. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?. Discov. Med. 2010, 9:173-178.
51. Fernandez D., Bonilla E., Mirza N., Niland B., Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 2006, 54:2983-2988.
52. Koyasu S. The role of PI3K in immune cells. Nat. Immunol. 2003, 4:313-319.
53. Weichhart T., Saemann M.D. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann. Rheum. Dis. 2008, 67(Suppl. 3):iii70-iii74.
54. Fruman D.A., Cantley L.C. Phosphoinositide 3-kinase in immunological systems. Semin. Immunol. 2002, 14:7-18.
55. Suarez-Fueyo A., Barber D.F., Martinez-Ara J., Zea-Mendoza A.C., Carrera A.C. Enhanced phosphoinositide 3-kinase delta activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. J. Immunol. 2011, 187:2376-2385.
56. Maxwell M.J., Tsantikos E., Kong A.M., Vanhaesebroeck B., Tarlinton D.M., Hibbs M.L. Attenuation of phosphoinositide 3-kinase delta signaling restrains autoimmune disease. J. Autoimmun. Jun 2012, 38(4):381-391.
57. Barber D.F., et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 2005, 11:933-935.
58. Kyttaris V.C., Wang Y., Juang Y.T., Weinstein A., Tsokos G.C. Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. J. Immunol. 2007, 178:1960-1966.
59. Mulero M.C., et al. Inhibiting the calcineurin-NFAT (nuclear factor of activated T cells) signaling pathway with a regulator of calcineurin-derived peptide without affecting general calcineurin phosphatase activity. J. Biol. Chem. 2009, 284:9394-9401.
60. Kyttaris V.C., Zhang Z., Kampagianni O., Tsokos G.C. Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum. 2011, 63:2058-2066.
61. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011, 21:381-395.
62. Tarakhovsky A. Tools and landscapes of epigenetics. Nat. Immunol. 2010, 11:565-568.
63. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
64. Ballestar E. Epigenetic alterations in autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 2011, 7:263-271.
65. Hedrich C.M., Tsokos G.C. Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends Mol. Med. 2011, 17:714-724.
66. Vojinovic J., et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011, 63:1452-1458.
67. Nicodeme E., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
68. Javierre B.M., Richardson B. A new epigenetic challenge: systemic lupus erythematosus. Adv. Exp. Med. Biol. 2011, 711:117-136.
69. Zouali M. Epigenetics in lupus. Ann. N. Y. Acad. Sci. 2011, 1217:154-165.
70. Javierre B.M., et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 2010, 20:170-179.
71. Jeffries M.A., Sawalha A.H. Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents. Int. J. Clin. Rheumatol. 2011, 6:423-439.
72. Hedrich C.M., Rauen T., Tsokos G.C. cAMP-responsive element modulator (CREM)alpha protein signaling mediates epigenetic remodeling of the human interleukin-2 gene: implications in systemic lupus erythematosus. J. Biol. Chem. 2011, 286:43429-43436.
73. Hedrich C.M., Rauen T., Kis-Toth K., Kyttaris V.C., Tsokos G.C. cAMP-responsive element modulator alpha (CREMalpha) suppresses IL-17F protein expression in T lymphocytes from patients with systemic lupus erythematosus (SLE). J. Biol. Chem. 2012, 287:4715-4725.
74. Mishra N., Reilly C.M., Brown D.R., Ruiz P., Gilkeson G.S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 2003, 111:539-552.
75. Reilly C.M., et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J. Immunol. 2004, 173:4171-4178.
76. Reilly C.M., et al. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J. Autoimmun. 2008, 31:123-130.
77. Tarkowski A., Gunnarsson K., Nilsson L.A., Lindholm L., Stalhandske T. Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator. Arthritis Rheum. 1986, 29:1405-1409.
78. Tarkowski A., Gunnarsson K., Stalhandske T. Effects of LS-2616 administration upon the autoimmune disease of (NZB×NZW) F1 hybrid mice. Immunology 1986, 59:589-594.
79. Jonsson S., et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J. Med. Chem. 2004, 47:2075-2088.
80. Bjork P., et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009, 7:e97.
81. Foell D., Wittkowski H., Vogl T., Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol. 2007, 81:28-37.
82. Vogl T., et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 2007, 13:1042-1049.
83. Lood C., et al. Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus. Arthritis Res. Ther. 2011, 13:R60.
84. Loser K., et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat. Med. 2010, 16:713-717.
85. Carlsten H., Jonsson C., Bokarewa M., Svensson L., Tarkowski A. The impact of a new immunomodulator oxo-quinoline-3-carboxamide on the progression of experimental lupus. Int. Immunopharmacol. 2004, 4:1515-1523.
86. Bengtsson A.A., et al. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Arthritis Rheum. 2012, 64:1579-1588.
87. Bengtsson A., Sturfelt G., Ronnblom L., Gunnarsson I., Svenungsson E., Jacobsen S., Lood C., Sparre B., Wallen Ohman M., Tuvesson H., Leanderson T. An exploratory study to evaluate changes in disease activity and biomarkers during treatment with ABR-215757 in patients with mild active systemic lupus erythematosus (SLE) 2011, European League Against Rheumatism Annual Congress 2011 (EULAR), [THU0417].
88. Comi G., et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 2012, 366:1000-1009.
89. Kaye J., Etzyoni R., Keshet-Katz R., Raymond E., Blaugrund E. Laquinimod Inhibits Disease Severity and Progression in Mouse Models of Lupus: Alone and in Combination with Standard of Care Agents 2011, ACR, [Presentation number: 560].
90. San Miguel J.F., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 2008, 359:906-917.
91. Kane R.C., et al. Bortezomib for the treatment of mantle cell lymphoma. Clin. Cancer Res. 2007, 13:5291-5294.
92. Meister S., et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007, 67:1783-1792.
93. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
94. Neubert K., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 2008, 14:748-755.
95. Slifka M.K., Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr. Opin. Immunol. 1998, 10:252-258.
96. Starke C., Frey S., Ubronaviciute V., Schett G., Winkler T., Voll R. Depletion of autoreactive short- and long-lived plasma cells within nephritic kidneys of lupus mice by bortezomib 2011, European League Against Rheumatism Annual Congress 2011 (EULAR), [OP0072].
97. Hainz N., et al. The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture. Nephron Exp. Nephrol. 2012, 120:e47-e58.
98. Badros A., et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007, 110:1042-1049.
99. Ichikawa H.T., et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum. 2012, 64:493-503.
100. Seavey M.M., Lu L.D., Stump K.L., Wallace N.H., Ruggeri B.A. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int. Immunopharmacol. 2012, 12:257-270.
101. Voll R.E., Alexander T., Peukert R., Rubbert A., Rech J., Braun T., Wiesener M., Eckardt K.-U., Hoyer B., Taddeo A., Reisch A., Burmester G.-R., Radbruch A., Schett G., Freiburg F. Successful treatment of refractory SLE patients with the proteasome inhibitor bortezomib - a case series 2012, European League Against Rheumatism Annual Congress 2011 (EULAR), [SAT0203].
102. Kyttaris V.C., Tsokos G.C. Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus. Curr. Opin. Rheumatol. 2011, 23:449-453.
103. Crispin J.C., Kyttaris V.C., Terhorst C., Tsokos G.C. T cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 2010, 6:317-325.